The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Loqtorzi Market Progress Through 2030?
Historical expansion was largely due to higher NPC diagnosis rates in endemic regions, advancements made in immunotherapy research, the initial successful outcomes of PD-1 blockade trials, increased funding for oncology research, and the proliferation of specialty cancer centers.
The anticipated growth during the forecast period is fueled by several factors, including a rise in global approvals for immunotherapy medications, increased investment directed towards treatments for rare cancers, expanded access to oncology biologics, the growing application of combination immunotherapies, and continuous innovation within immune modulation therapies. Concurrently, significant trends expected over this period encompass the increasing adoption of PD-1 inhibitors in addressing rare cancers, a heightened focus on the treatment of nasopharyngeal carcinoma, the expansion of immuno-oncology research and development pipelines, a surge in the use of immune checkpoint blockade therapies, and enhanced global clinical trial activities.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20148&type=smp
Which Significant Factors Are Encouraging Growth In The Loqtorzi Market?
The increasing prevalence of nasopharyngeal carcinoma is projected to drive the expansion of the loqtorzi market in the foreseeable future. Nasopharyngeal carcinoma is a form of cancer that impacts the nasopharynx and is closely associated with Epstein-Barr virus infection, with early diagnosis being crucial for treatment outcomes. The growth in nasopharyngeal carcinoma prevalence can be attributed to elements such as elevated exposure to the Epstein-Barr virus, genetic predispositions, environmental factors including tobacco and alcohol use, and dietary practices, particularly the intake of salted and preserved foods. Loqtorzi (toripalimab) assists nasopharyngeal carcinoma (NPC) patients by strengthening the immune system’s capability to target cancer cells through the inhibition of the PD-1 pathway, thereby presenting a novel treatment option for those with recurrent or metastatic NPC, either in conjunction with chemotherapy or as a standalone therapy following disease progression. For example, in October 2024, according to the Cancer Research UK, a UK-based registered charity, the incidence of head and neck cancer in the UK is anticipated to increase by 3% when comparing the 2023–2025 period with 2038–2040. Thus, the escalating prevalence of nasopharyngeal carcinoma is a significant driver for the growth of the loqtorzi market.
Which Segment Divisions Form The Structure Of The Loqtorzi Market?
The loqtorzi market covered in this report is segmented –
1) By Formulation: Injectable Formulation (intravenous), Lyophilized Powder For Reconstitution
2) By Indication: Treatment Of Small Cell Lung Cancer (SCLC), Treatment Of Other Solid Tumors
3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions
What Trends Are Influencing The Loqtorzi Market Outlook?
A significant trend within the Loqtorzi market centers on the development of biosimilars to expand portfolios and provide more economical treatment alternatives to existing biologic therapies. Biosimilars are biologic products closely resembling an approved reference product, demonstrating no clinically meaningful differences in safety or effectiveness. They present an affordable option to expensive biologic drugs once the original product’s patent expires. For example, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, introduced a biosimilar of Coherus BioSciences’ (CHRS) Loqtorzi (toripalimab) in India under the brand name Zytorvi. This drug is indicated for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare cancer. Loqtorzi received FDA approval in October 2023 for the first-line treatment of RM-NPC in combination with cisplatin and gemcitabine, and as a monotherapy for patients with disease progression after platinum-based chemotherapy. It remains the only FDA-approved immuno-oncology drug for this specific indication.
Who Are The Key Market Participants In The Loqtorzi Market?
Major companies operating in the loqtorzi market are Coherus BioSciences Inc., Shanghai Junshi Biosciences Co. Ltd.
Access The Complete Loqtorzi Market Report:
https://www.thebusinessresearchcompany.com/report/loqtorzi-global-market-report
Which Region Accounts For The Highest Share Of The Loqtorzi Market?
North America was the largest region in the loqtorzi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the loqtorzi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model